Our Commitment to Patient Data Security and Privacy: Ongoing SOC 2®, Type II Certification

SOC 2 certification aligns Reverba with world-class organizations achieving the highest level of security and compliance for data management for service organizations – SEATTLE – April 20, 2023 – Reverba, a leading global patient engagement company, announces that it has successfully reaffirmed the Service Organization Control (SOC) 2, Type II certification for 2023, completing this important…

SOC 2 certification aligns Reverba with world-class organizations achieving the highest level of security and compliance for data management for service organizations –

SEATTLE – April 20, 2023 – Reverba, a leading global patient engagement company, announces that it has successfully reaffirmed the Service Organization Control (SOC) 2, Type II certification for 2023, completing this important security audit for the seventh time and maintaining its certification continuously since 2016. To comply with SOC 2, Reverba demonstrated it has established and utilizes rigorous policies and procedures for security and confidentiality in its data processing systems and with subcontractors and vendors, maintaining the highest level of data security and compliance. For more than 20 years, Reverba has been leading innovation in patient engagement by providing high-tech high-touch solutions for patient engagement, empowering biopharmaceutical companies to connect with patients as they advance their products throughout the product lifecycle. Having this designation allows Reverba to ensure compliance while making patient-centered action possible for their clients.

“We’re incredibly proud of this accomplishment, as data privacy and security have become a central concern for biopharmaceutical companies and the patients they serve. SOC 2 Type II certification touches on all aspects of our business operations, and it creates an important level of trust between Reverba and the companies who rely on us to provide patient engagement solutions,” said Cheryl Lubbert, CEO and co-founder of Reverba. “We’ve maintained our SOC 2, Type II certification for seven consecutive years as it reinforces our ongoing commitment to the security, compliance and processing integrity of our platform and solutions.”

This widely recognized auditing standard was developed by the American Institute of Certified Public Accountants (AICPA). Reverba’s SOC 2 audit was conducted by Moss Adams, a top 15 independent auditor with over 100 years in business including serving as an independent expert in security testing and compliance certifications for service companies worldwide. Reverba maintains SOC 2, Type II certification in accordance with AICPA Attestation Standards and IAASB ISAE No. 3000 (Revised) Standards.

A copy of Reverba’s SOC 2, Type II report is available to clients and prospects upon request.

About Reverba:

Reverba is a global patient engagement company that creates transformative tech-enabled solutions to build a bridge between patients and biopharmaceutical companies, from discovery to clinical development through commercialization. Utilizing its clinical and commercial divisions, Reverba provides comprehensive custom patient engagement solutions with its proprietary reverbaBRIDGE™ technology platform. Reverba infuses compliance throughout its technology platforms and patient engagement solutions, maintaining SOC 2, Type II certification for the highest level of security. For more information, visit www.reverba.com or contact connect@reverba.com

Media Contact:
Kathy Fallon
Kathy.fallon@reverba.com
610-952-3223


The Latest

  • Cheryl Lubbert, CEO of Reverba Global, Named 2026 HBA Luminary Award Honoree
    Cheryl Lubbert, CEO of Reverba Global, Named 2026 HBA Luminary Award Honoree

    Cheryl Lubbert, CEO of Reverba Global, has been named a 2026 HBA Luminary Award honoree by the Healthcare Businesswomen’s Association. The recognition reflects her leadership in advancing scientific engagement and…

  • Perspective From Patients as Partners: Sustaining Patient Engagement Through Organizational Changes
    Perspective From Patients as Partners: Sustaining Patient Engagement Through Organizational Changes

    At Patients as Partners 2026, CEO Cheryl Lubbert shared how sustaining patient engagement through organizational change requires intentional design, with systems built to hold as teams, priorities, and programs shift.

  • Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?
    Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?

    AI is becoming a baseline expectation in pharma. At Pharma USA 2026, discussions reflected less focus on whether AI should be used and more on how it is being applied…